Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 804 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GLP-1 Clear all
Recruiting Phase 2 Interventional

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081
View directory record Official record
Conditions
Atrial Fibrillation, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Terminated Phase 3 Interventional Results available

Binge Eating Liraglutide Intervention

NCT03279731
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
Drug
Lead sponsor
Kelly Allison
Other
Eligibility
21 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 17, 2026, 6:22 PM EDT
Recruiting Phase 4 Interventional

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

NCT06774079
View directory record Official record
Conditions
Crohn Disease
Interventions
Tirzepatide, Mediterranean diet
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

NCT00620282
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

NCT02660242
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 17, 2026, 6:22 PM EDT
Recruiting Phase 2 Interventional

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324
View directory record Official record
Conditions
Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
Interventions
Tirzepatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional

Lifestyle Change Implementation Research Network at PRC at UMass Chan

NCT07481305
View directory record Official record
Conditions
GLP - 1
Interventions
Digital Lifestyle Coaching Program
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Terminated No phase listed Observational

RESCUE: Discontinuation of GLP-1

NCT07190794
View directory record Official record
Conditions
Obesity
Interventions
OverStitch™ or OverStitch NXT™, Lifestyle Modification
Device · Behavioral
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

NCT06515418
View directory record Official record
Conditions
Obesity
Interventions
Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
55 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 1 Interventional

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

NCT06916065
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide and Tirzepatide, Eloralintide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Results available

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

NCT04387201
View directory record Official record
Conditions
Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
Interventions
Cyanocobalamin, Dulaglutide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Not applicable Interventional Results available

Four Way Crossover Closed Loop With Exercise Detection

NCT02862730
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 6:22 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

GLP-1 RA for Stage 1 Type 1 Diabetes

NCT07430332
View directory record Official record
Conditions
Stage 1 Diabetes Mellitus, Type 1
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans

NCT04392843
View directory record Official record
Conditions
Hypoglycemia
Interventions
Fasting, Feeding
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

NCT05978713
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126
View directory record Official record
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Obesity and Insulin Resistance

NCT04926415
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
taVNS, Sham taVNS
Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 17, 2026, 6:22 PM EDT
Terminated Not applicable Interventional

Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation

NCT06273163
View directory record Official record
Conditions
Obesity
Interventions
Medically tailored meals, Noom®, Usual care
Other · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 17, 2026, 6:22 PM EDT
Completed No phase listed Observational

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

NCT01153438
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Bariatric Surgery
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 17, 2026, 6:22 PM EDT
Completed Phase 1 Interventional Results available

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

NCT05696847
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 17, 2026, 6:22 PM EDT
Completed No phase listed Observational

Effects of GLP-1 Agonists on Gastric Volume

NCT05854979
View directory record Official record
Conditions
Diabetes, Gastric Content Aspiration, Glucagon-like Peptide 1, GLP-1
Interventions
Gastric Ultrasound
Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 17, 2026, 6:22 PM EDT
Active, not recruiting Phase 4 Interventional

GLP-1s to Enhance Lasting Optimal Weight

NCT06861439
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions
Gastric Fundal Mucosal Ablation (GFMA)
Device
Lead sponsor
Dr. Christopher McGowan
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 17, 2026, 6:22 PM EDT